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Abstract 
Colorectal cancer (CRC) is the third most common cancer worldwide and has a 
complex aetiology consisting of environmental and genetic factors. In this review, we 
evaluate the roles of alcohol and tobacco smoking in colorectal neoplasia. Alcohol 
intake and tobacco smoking are associated with modest, but significantly, increased 
risks of CRC, adenomatous and serrated polyps. There is consistent evidence of dose-
response relationships for both alcohol and smoking, and risk of these neoplasms. 
Alcohol and smoking appear to be more strongly associated with colorectal polyp 
than CRC development, suggesting roles in the initiation of neoplastic growths. These 
lifestyle factors also seem more strongly related to adenomas and sessile serrated 
lesions than hyperplastic polyps, but further confirmation is required. The 
gastroenterology community has an important, yet currently underexploited, role to 
play addressing the modifiable factors associated with CRC and polyps. These 
behaviours include, but are not limited to, alcohol and smoking.    
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Colorectal cancer (CRC) is a multifactorial disease of complex aetiology 
encompassing both genetic and environmental factors [1].  It arises from the gradual 
accumulation of pathogenic mutations in normal colonic mucosa [1,2]. 
Approximately 95% of CRCs are classified as adenocarcinomas, which originate in 
the colorectal mucous-producing glands [1].  Other types of CRC are rare [3].  
 
Pathogenesis of colorectal neoplasms (A) 
CRC is initiated when mutations result in the malignant transformation of 
preneoplastic polyps [1,4].  In the past, adenomas and hyperplastic polyps were 
considered to be the two main subgroups of epithelial colorectal polyps [2,5]. 
Adenomas were regarded as the sole precursor lesions of CRC whilst hyperplastic 
polyps were believed to possess no malignant potential [5,6]. This hypothesis has 
since been partially negated, and the umbrella term ‘serrated polyp’ is now used to 
encompass benign hyperplastic polyps, as well as sessile serrated lesions and 
traditional serrated adenomas, with the latter two forms of serrated polyp both  
considered to harbour neoplastic potential [7] (Figure 1). Conventional adenomas and 
serrated polyps are morphologically distinct, arising from two genetically and 
epigenetically different pathways with unique clinical manifestations [8,9].  
 
Adenoma-carcinoma sequence (B) 
Adenomatous polyps can progress to CRC via the traditional pathway known as the 
adenoma-carcinoma sequence, which refers to a classical stepwise molecular 
progression from normal colorectal mucosa, through dysplasia and ultimately to 
invasive adenocarcinoma [10,11].  The inactivation of the adenomatous polyposis coli 
(APC) tumour suppressor gene leads to oncogene activation, and is key to adenoma 
development [12]. 
 
Serrated polyp-carcinoma pathway (B) 
Serrated polyps provide an alternative pathway to CRC via the serrated polyp-
carcinoma pathway, which is estimated to account for between 10% and 30% of 
CRCs [9]. Abnormal DNA methylation is key to the development of this type of CRC 
[13].   
 
Histologically, the characteristic feature of serrated polyps is infolding of the crypt 
epithelium, producing a stellate appearance in cross-section and a saw-toothed or 
serrated appearance in longitudinal section [14].  Endoscopically, hyperplastic polyps 
and sessile serrated lesions have a similar, pale, appearance and their boundaries with 
the surrounding normal mucosa are often not clearly demarcated [15]. They differ 
however in size and site, with sessile serrated lesions commonly larger and more 
proximally located than hyperplastic polyps. 
 
Epidemiology of colorectal cancer (A) 
Colorectal cancer is the third most common cancer worldwide [16], accounting for 
more than 9.7% of all cancer incidence in 2012 [17].  Each year, almost 1.4 million 
new cases are diagnosed, making CRC a major cause of morbidity and mortality 
globally [18] and the fourth most common cause of cancer death [16]. The highest 
age-standardised incidence rates have been recorded in Australia, New Zealand, 
Canada, the United States (US) and parts of Europe [18] (Figure 2).  
 
However, CRC incidence rates appear to be stabilising in many high-income settings 
[19], which may in part reflect improved early detection through screening 
programmes and prevention through polypectomy [16]. A decline in mortality from 
CRC in these regions can also be attributed to improvements in treatments including 
radiotherapy and chemotherapy [20,21]. Conversely, CRC incidence and mortality is 
quickly rising in several medium-to-high Human Development Index countries with 
this trend being particularly notable in parts of Eastern Europe, Asia and South 
America [16]. On the basis of projected demographic changes, the World Health 
Organization expects an increase in the global burden of CRC, with an estimated 77% 
increase in newly diagnosed CRC cases and an 80% increase in CRC deaths by 2030 
[1,22,23]. 
 
It is therefore important to clarify the role of modifiable risk factors, such as alcohol 
consumption and tobacco smoking, in CRC development, in order to identify 
preventative strategies that could reduce this projected increase in CRC burden.  
 
Risk factors for colorectal cancer (B) 
A small proportion (approximately 5%) of CRC is attributable to known genetic 
predisposition syndromes, such as familial adenomatous polyposis and Lynch 
syndrome (formerly known as hereditary non-polyposis colorectal cancer) [24,25]. 
Individuals with chronic idiopathic inflammatory bowel disease (chronic ulcerative 
colitis or Crohn’s disease) are also at an increased risk of CRC compared with the 
general population, although actual risk is still low - for example, an estimated 0.8% 
of patients with chronic ulcerative colitis develop CRC each year [26].  
 
Colorectal cancer is also associated with a number of modifiable risk factors and it 
has been estimated that between 66% and 75% of CRC cases are preventable 
[1,18,27].  A number of studies have associated aspects of a western lifestyle, such as 
obesity, physical inactivity and high red-meat consumption, with increased CRC risk 
[28,29].   
 
In their 2011 report (due to be updated in 2017), the World Cancer Research 
Fund/American Institute for Cancer Research (WCRF/AICR) judged the strength of 
evidence for a number of risk factors associated with CRC [30]. This report found 
‘convincing’ evidence that both physical activity and foods containing dietary fibre 
decrease CRC risk, whilst red meat, processed meat, body fatness, abdominal fatness, 
and adult attained height were all associated with an increased risk of developing 
CRC [30]. Furthermore, the WCRF/AICR report stated that it is ‘probable’ that a 
decreased risk of CRC is associated with high intakes of garlic, milk and calcium. The 
WCRF/AICR report did also judge that alcoholic drinks increase the risk of CRC, but 
reported convincing evidence in men and only probable evidence of this association 
in women [30].  
 
There is also evidence that non-steroidal anti-inflammatory drugs, aspirin [31,32], and 
hormone replacement therapy in postmenopausal women decrease CRC risk [33,34].  
For the purposes of this review, we focus on evaluating the evidence investigating 
alcohol consumption, tobacco smoking and risk of CRC and colorectal polyps, 
respectively.  It is worth highlighting that the majority of studies described utilise 
self-report measures of alcohol intake and smoking, which are often subject to 
response biases, and so the following evidence summary may reflect underestimates 
of associations between these lifestyle factors and colorectal neoplasia. 
 
 
Alcohol and colorectal cancer risk (A) 
The association between alcohol and colorectal neoplasia risk is summarised in Table 
1. In 2007, a working group for the International Agency for Research on Cancer 
(IARC) reviewed epidemiological evidence from over 50 studies that reported on the 
association of alcohol consumption and 27 anatomical sites including the 
colon/rectum [35]. IARC concluded that there was sufficient evidence to support the 
addition of CRC to the list of malignancies causally related to alcohol [36,37]. As 
outlined above, this association has also been confirmed by the 2011 WCRF/AICR 
report on CRC risk factors [30]. A further analysis conducted in 2015 has combined 
results from 2 cohort studies and 22 case-control studies, and  revealed that the pooled 
relative risk (RR) of CRC for any drinkers in comparison with non-drinkers and 
occasional drinkers is 1.13 (95% confidence interval (CI), 1.09-1.17) [38].  
 
There is also consistent evidence of a dose-response association between alcohol and 
CRC risk [38–40]For light, moderate and heavy drinking (defined as ≤1, 2-3 and ≥4 
drinks/day, respectively),  the RR were 1.07 (95% CI, 1.02-1.13),  1.23 (95% CI, 
1.15-1.32) and 1.37 (95% CI, 1.26-1.49), respectively [38].  Meta-regression analysis 
within the same study confirmed the presence of a significant, direct, dose-response 
relationship between alcohol intake and CRC risk [38].  Similar findings were noted 
in previous research that estimated that compared to occasional and non-drinkers, 
individuals that consume at least 4 drinks a day are 52% more likely to develop CRC 
[39].    Subgroup analyses within studies have also found similar increased risks for 
higher alcohol consumption across tumor sites (i.e. colon or rectum) [38,40] .   
 
The biological plausibility of a dose-response relationship is supported by an in vitro 
study on genotoxicity of ethanol and acetaldehyde on gastrointestinal tract mucosa 
cells. Blasiak et al identified a dose-dependent increase in breaks in colonic mucosa 
DNA strands with ethanol exposure [41]. Acetaldehyde has also been implicated in 
folate degradation [3] which can lead to chromosome breakage and misappropriation 
of uracil [42]. This is a key underlying mechanism by which alcohol is thought to 
promote colorectal carcinogenesis.   
 
Alcohol, age at onset, and colorectal cancer risk (B) 
Regular alcohol consumption has also been implicated in the development of CRC at 
a younger age, and is associated with distal location of these tumours [43].  Recently, 
there has been concern over rising CRC incidence in adults aged under 50 years, 
which has been particularly notable for rectal cancers [44–46]. In analysis of 161,172 
CRC patients comparing self-reported current (within the past year), past (quit at least 
1 year prior to diagnosis) and never drinkers of alcohol revealed that were was a 
lower age of onset for CRC amongst alcohol drinkers [43]. Amongst CRC cases, 
current and past use of alcohol was linked to being diagnosed, on average, 5.2 and 2.1 
years younger than never drinkers with  CRC diagnosis (P<.001 for both). However, 
this study was somewhat limited by their categorization of ‘past drinker’, which is 
likely to be a heterogeneous group [43]. Further research is required to determine if 
changing patterns of alcohol and other lifestyle factors, such as obesity, may be 
contributing to the overall observed decline in CRC age at onset [45].    
 
Alcohol types and colorectal cancer risk (C) 
Existing evidence for beverage-specificity with regard to CRC risk is inconsistent 
[47–49]. The European Prospective Investigation into Cancer and Nutrition-Norfolk 
(EPIC-Norfolk) study demonstrated a significant inverse association between daily 
consumption of one glass of wine and overall CRC risk with a hazard ratio (HR) of 
0.61 (95% CI: 0.40–0.94) [49]. The risk with wine was postulated to be to be lower in 
rectal cancers than in colon cancers, although this may have been a consequence of 
the small number of rectal cases within this study. Similar findings were observed in a 
subsequent study, which identified a borderline significant inverse association 
between wine consumption (1-5 glasses per week) and CRC (HR 0.86 (95% CI: 0.73–
1.01)) [48]. Again, the association appeared to be stronger in rectal cancers (HR 0.62, 
95% CI: 0.47–0.83) [48]. Existing literature does indicate that wine has anti-
carcinogenic and protective properties for other cancers, which may explain the 
inverse relationship observed between light-moderate wine intake and CRC [50–52].  
 
In the EPIC study, beer intake was also associated with a significant 38% increased 
risk of CRC (HR 1.38, 95% CI 1.08-1.77 for 20-39.9 vs. 0.1-2.9 g/day) [49]. Spirits 
and liquor were associated with non-significant increased risk of rectal cancers only 
(1.27, 95%CI 0.96–1.69 for >5 g/day vs. 0.1–1.9 g/day) [49].  
 
Overall, it is very difficult to distinguish alcohol types when advising patients and the 
general public about their alcohol consumption, with specific regards to CRC 
prevention. The WCRF/AICR recommend that individuals limit their alcohol intake 
and follow national guidelines, if consumed at all, but advise against alcohol 
consumption for purposes of cancer prevention [53].  
 
Alcohol and colorectal polyp risk (A) 
When evaluating evidence for polyp risk, it is crucial to consider study designs. Due 
to the asymptomatic nature of many colorectal polyps, it is important that controls (i.e. 
individuals without polyps) in such studies have had the opportunity for a polyp to be 
diagnosed i.e. that all underwent an endoscopy.  For a number of studies reporting on 
alcohol, smoking and polyp risk, the sole method of assessment for the colon was 
sigmoidoscopy, as opposed to a full colonoscopy.   Therefore, risk of proximal right-
sided adenomas and serrated polyps often cannot be estimated.  Additionally, unlike 
CRC outcomes, general cohort studies are not appropriate, and only case-control or 
nested case-control studies within cohort/trial participants who undergo endoscopy, 
can truly assess polyp outcomes.  This in turn has consequences for recall bias, and 
likely underreporting of alcohol/smoking behaviours in case-control studies that may 
underestimate true associations with colorectal polyp risk.   
Alcohol and colorectal adenoma risk (B) 
The association between alcohol consumption and risk of colorectal adenomas has 
been investigated in several observational studies.  A meta-analysis of 23 case-control 
studies and 2 nested case-control studies within cohorts compared all drinkers to non-
drinkers, and found  summative RRs of colorectal adenoma were 1.17 (95% CI 1.11–
1.22) in case–control studies and 1.08 (95% CI 0.88–1.33) in the nested case-control 
studies, respectively [54].  
 
Again, a dose-response relationship between alcohol and colorectal adenomas was 
observed, demonstrating that individuals who consumed 10, 25, 50 and 100g of 
alcohol per day, had RRs of developing colorectal adenoma of 1.02 (95% CI 0.89–
1.16), 1.06 (95% CI 0.92–1.20), 1.16 (95% CI 1.02–1.33) and 1.61 (95% CI 1.42–
1.84), respectively, compared with occasional and non-drinkers [54].   This 
association was consistent for both males and females [54].   The link did, however, 
appear to be stronger in European studies compared to those conducted in Asia or the 
US [54]. This may be a reflection of variations in screening guidelines, as well as due 
to genetic factors. In keeping with previous meta-analyses of CRC [39,54], risk of 
colorectal adenoma did not differ according to different anatomical sites of the colon 
and rectum [54].  
Alcohol and serrated polyp risk (B) 
Alcohol has also been linked with an increased risk of serrated polyps.  A recent 
meta-analysis of studies comparing high versus low alcohol consumption with regard 
to serrated polyp development revealed a significant increased risk of overall serrated 
polyps (RR 1.33; 95% CI, 1.17−1.52) [2].  The magnitude of this increased risk was 
found to be greater for sessile serrated lesions (also known as sessile serrated 
adenomas/polyps) (RR 1.85; 95% CI, 1.03−3.32), but still evident for hyperplastic 
polyps (RR, 1.30; 95% CI, 1.15−1.48) [2].  The meta-analysis was slightly limited by 
many studies reporting on hyperplastic polyp outcomes potentially including some 
sessile serrated lesions that were misclassified as benign hyperplastic polyps. 
Therefore further research is required in studies that carefully review and distinguish 
these serrated polyp subtypes, in order to confirm the stronger influence of alcohol on 
sessile serrated lesions compared with hyperplastic polyps.   
 
Smoking and colorectal cancer risk (A) 
The association between smoking and colorectal neoplasia risk is summarised in 
Table 2.  Tobacco smoke is a well established carcinogen, and research confirms that 
there is a significant association between smoking and CRC risk.  Large, multicentre 
cohort studies and meta-analyses have demonstrated that this association is present for 
both past and current smokers [55,56].  Results indicate a significant 38% increased 
CRC risk in current smokers (RR, 1.38; 95% CI, 1.22–1.56), while former smokers 
have an 18% increased risk of CRC (RR, 1.18; 95% CI, 1.12–1.25), compared  with 
never smokers [56].  Although former smokers still experience this increased CRC 
risk compared with never smokers, the reduced magnitude of the association 
compared with current smokers indicates some evidence of a benefit for smoking 
cessation in reducing CRC risk.  
Dose-response effects of smoking have also been clearly demonstrated when 
considering tobacco exposure as number of years smoking, total number of pack-
years or the number of cigarettes consumed daily [56,57].  Individuals who have 
smoked for <30 pack-years have an estimated 19% increased CRC risk, while those 
who smoked for ≥30 pack-years have a 28% increased CRC risk, compared with 
never-smokers [56]. This has also been quantified as a 6% increased CRC risk per 
additional 5 years pack-years of smoking [58].  A meta-analysis of 11 studies has also 
identified modest, but significant, increased risks of CRC associated with passive 
smoking [59]. Overall though, it is notable that the magnitude of the increased CRC 
risk associated with smoking is much lower than that seen for upper gastrointestinal 
cancers [60,61].  A review published in JAMA has estimated that tobacco smoking 
contributes an absolute risk of 11 additional CRC cases per 100,000 person years of 
follow-up [57].  
As with alcohol, the role for smoking in colorectal neoplasia is biologically plausible. 
Tobacco smoke is inundated with carcinogens such as aromatic amines, nitrosamines, 
heterocyclic amines and polycyclic aromatic hydrocarbons [62]. Following 
metabolism by the cytochrome P450 system, these compounds can lead to the 
production of abnormal DNA and mutations in genes implicated in CRC such as 
KRAS and BRAF [63], the latter of which is particularly prevalent in serrated 
colorectal neoplasms.  
 
Smoking, location and molecular subtypes of colorectal cancer risk (B) 
There appears to be consistent evidence that tobacco smoking is more strongly 
associated with both rectal and right-sided colon cancer risk, compared with left-sided 
colon cancers [62,63].  In their meta-analysis, Cheng et al reported increased CRC 
risks in smokers compared with non-smokers, but identified 24% and 9% increases 
for rectal versus colon cancers, and greater risks for proximal versus distal colon 
cancers (summary RRs 1.31; 95% CI, 1.13–1.52; and 0.98, 95% CI, 0.84–1.14, 
respectively, p=0.03) [64].  It will therefore be useful for studies to ascertain whether 
there are different pathogenic mechanisms underlying colonic and rectal cancers. An 
overall stronger association between smoking and CRC in males compared with 
females has also been hypothesised to occur as a result of divergent patterns of 
chromosomal mutations [56,65,66].    
 
A comprehensive systematic review of smoking history, molecular pathways and 
CRC risk has found that smoking is associated with tumours that are P53 and/or 
BRAF mutant, demonstrate high microsatellite instability (MSI-high) and are CIMP 
positive, but smoking was not implicated in the aetiology of APC or KRAS mutant 
CRC [67].  Furthermore, smoking has also been associated with increased risks of 
synchronous CRC that are MSI-high, CIMP positive or BRAF mutant [68]. 
Collectively, this suggests stronger involvement of tobacco smoking in the colorectal 
serrated pathway, compared with the adenoma-carcinoma sequence. 
  
Smoking and colorectal polyp risk (A) 
Smoking and Colorectal adenoma risk (B) 
Studies consistently report that there  is a significantly greater proportion of colorectal 
adenomas amongst smokers compared with non-smokers [69,70].  A meta-analysis of 
42 observational studies demonstrated pooled risk estimates for colorectal adenoma in 
current, former and ever smokers of 2.14 (95% CI, 1.86-2.46), 1.47 (95% CI, 1.29-
1.67), and 1.82 (95% CI, 1.65-2.00), respectively [69]. Again, clear dose-response 
associations between smoking and adenoma risk have been noted [70].  
Disparities in the effects of smoking on the risk of developing a colorectal adenoma 
appears to be more pronounced in men than in women, with a risk at low smoking 
exposure (defined as ≤15 pack-years of smoking) being solely apparent in men [70]. 
It has been hypothesized that hormone replacement therapy [71,72] and higher 
prevalence of calcium supplement use among women, which both have protective 
effects against adenoma development, may explain these differences [73]. 
Smoking and serrated polyp risk (B) 
Smoking is commonly cited as a risk factor for serrated polyps and this association 
has been further clarified in a meta-analysis of 29 studies published in 2017 [2]. A 2.5 
fold increased serrated polyp risk was identified when comparing individuals with the 
highest to the lowest smoking exposure [2]. Although the risk was apparent for 
serrated polyps overall, there was a stronger association for sessile serrated lesions 
(RR, 3.40; 95% CI, 1.90−6.07) in comparison with hyperplastic polyps (RR, 2.34; 
95% CI, 2.00−2.73) [2].  
 
Although there is a strong body of evidence to support an association between 
smoking and the development of serrated polyps, the evidence on anatomical location 
of these is inconsistent. A study that included pooled data obtained from three large 
multi-centre chemoprevention trials showed that there was a link between smoking 
and the development of serrated polyps in the distal colon (RR 2.18; 95% CI 1.80-
2.65) but not the proximal colon (RR 1.11; 95% CI 0.80-1.54) [74]. These findings 
were corroborated in a case-control study in which, when non-smokers and current 
smokers were compared, no association was found between tobacco use and the 
development of proximal serrated polyps [75]. Similar to alcohol, further studies in 
which serrated polyps have been characterised according to current histological 
classification, and all participants have undergone full colonoscopy, would help to 
further clarify the magnitude of associations between smoking and risk of serrated 
polyp subtypes. 
 
Interventional studies addressing alcohol, smoking and colorectal neoplasia (A) 
For numerous health reasons beyond the association with CRC and colorectal polyps, 
individuals should be advised not to smoke tobacco. Advice regarding alcohol 
consumption is less straightforward but, generally, individuals should be advised to 
limit their intake if they consume alcohol. Although there are some nuances that 
deserve further study in observational settings, such as accurately quantifying the 
association between lifestyle factors and serrated polyp subtypes, or age at CRC onset, 
it is timely now for gastroenterological research to place greater attention on lifestyle 
interventions in order to reduce CRC burden.   
 
Overall, it is noteworthy that associations between alcohol and smoking appear to be 
stronger for colorectal polyp risk than CRC development (Tables 2 and 3). This could 
reflect limitations in study designs of polyp risk, that often require cross-sectional 
assessment of lifestyle habits, however, it may also point towards greater biological 
roles of alcohol and smoking in the initiation of neoplastic growths.  The diagnosis of 
pre-malignant colorectal polyps in an individual offers a valuable opportunity for a 
‘teachable moment’ in which to promote healthier lifestyle choices that include 
responsible alcohol consumption and being smoke-free. In this regard, the entire 
gastroenterology community has an important, but currently underexploited, role to 
play.  
 
Trials of lifestyle behaviours and polyp risk to date have (appropriately) not focussed 
specifically on smoking cessation or alcohol intake, likely due to the lower impact of 
these factors on risk compared with, for example, nutrition. The Polyp Prevention 
Trial in the US has sought to intervene to reduce recurrence in almost 2,000 
individuals who had been diagnosed with colorectal adenomas [76].  That 
intervention did not specifically target alcohol and smoking behaviours, but required 
individuals to adhere to a very strict low-fat, high-fibre, high fruit and vegetable diet. 
A 35% reduced odds of adenoma recurrence was observed amongst ‘super’ compliers 
to the intervention, demonstrating the success of a targeted intervention amongst this 
patient group [76].  A more recent intervention conducted in Scotland (the BeWEL 
intervention), has sought to aid weight loss and increase physical activity amongst 
329 individuals who had a colorectal adenoma diagnosis [77]. The BeWEL 
intervention has achieved successful weight loss outcomes, but the impact on future 
colorectal neoplasia risk is, as yet, unclear [77]. Both trials demonstrate the success of 
using this time (a colorectal adenoma diagnosis) and clinical setting to address 
behaviour change.  It would be interesting to conduct future health service 
interventions that incorporate alcohol and smoking lifestyle advice, to evaluate the 
impact on outcomes detected at follow-up colonoscopies.  These may be delivered by 
signposting individuals to supporting services, such as smoking cessation clinics or 
pharmacies [78], or be in the form of ‘brief intervention’ advice [79,80], due to time 
constraints in the clinical gastroenterology setting.  
 
Summary (A) 
There is a large body of evidence to support the role of both alcohol and smoking in 
colorectal neoplasia. Alcohol intake is associated with significantly increased risks of 
CRC, adenomatous and serrated polyps, and there is evidence of a dose-response 
relationship. These trends appear to be consistent across both genders and different 
anatomical sites within the colorectum.  With regards to smoking, there is a modest 
but significant increased risk of CRC and colorectal polyps, and again a dose-
response relationship has been identified, compared with never smokers. There are 
however gender differences and differences in risk according to anatomical sub-site, 
with greater risks for male smokers and for proximal colon and rectal tumours. There 
is also evidence of smoking influencing risk of distinct molecular subtypes of CRC, 
most notably BRAF, P53 mutant and MSI-high and CIMP-positive tumours.  Overall, 
alcohol and smoking appear to be more strongly associated with risk of colorectal 
polyps than CRC, per se. The diagnosis of colorectal polyp offers an opportune 
moment for gastroenterologists and the supporting health professional team to 
signpost individuals to smoking cessation services or offer advice on alcohol 
consumption as part of broader health promotion, as appropriate. Further molecular 
pathology epidemiology studies and interventional studies are warranted in this area.    
 
Practice points 
 Tobacco smoking and higher alcohol intake are associated with modest, but 
significant, increased risks of colorectal polyps and cancer 
 There is evidence that smoking is particularly implicated in the serrated 
colorectal pathway, and specific molecular subtypes of colorectal cancers 
 Individuals diagnosed with colorectal polyps should be offered appropriate 
lifestyle advice, that includes information on responsible alcohol consumption 
and smoking cessation, where appropriate 
Research agenda 
 With a few exceptions, such as the suggestions below, the era of observational 
studies for alcohol, smoking and colorectal polyp and cancer risk has now 
largely passed, due to conclusive findings that these contribute to increased 
risks of these neoplasms. Interventional studies addressing alcohol and 
smoking (and other) lifestyle behaviours are now required, particularly 
amongst individuals diagnosed with colorectal polyps.    
 The role of lifestyle factors, including alcohol and smoking, in the recent 
increase in CRC incidence in younger adults requires further investigation. 
 Quantifying the association between alcohol, smoking and serrated polyp 
subtypes requires further research in studies with standardised and current 
pathological reporting, to clarify potentially stronger associations for sessile 
serrated lesions than benign hyperplastic polyps. 
 Molecular pathology epidemiology research studies are required to fully 
explore the association between alcohol, smoking and colorectal neoplasms 
according to different molecular characteristics. 
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Figure Legends. 
Figure 1. Current classification of epithelial colorectal polyps. 
Figure 2. Worldwide colorectal incidence (age-standardised rates per 100 000) in Men 




Table 1. Summary of evidence for association between alcohol and colorectal neoplasms 
Neoplasm  Direction of 
association 
Strength of association Related notable findings Key 
References* 
Carcinoma Positive Any v. non/occasional 
drinking  
RR 1.13 (95% CI 1.09-1.17) 
 
Dose-response associations for light, moderate 
and heavy drinking.  
[38] 
Adenoma Positive Any v. non-drinking  
RR 1.17 (95% CI 1.11-1.22) 
Dose-response associations for light, moderate 
and heavy drinking.  
Associations were weaker in nested case-control 
studies.  
Associations were stronger in European studies 




Positive High v. low alcohol drinking 
RR 1.33 (95% CI 1.17-1.52) 
  
Association was stronger for sessile serrated 
lesions compared with hyperplastic polyps and 
traditional serrated adenomas. 
[2] 
 
RR: Relative Risk. CI: Confidence Intervals. *References pertain to the risk estimates shown in the most recently published meta-analyses.           
Further studies are referenced in the relevant corresponding text of the review.  
 
Table 2. Summary of evidence for association between smoking and colorectal neoplasms 
Neoplasm  Direction of 
association 
Strength of association Related notable findings Key 
References* 
Carcinoma Positive Current v. never smoking  
RR 1.38 (95% CI 1.22-1.56)  
Dose-response association observed. 
Smoking is related to specific molecular subtypes, 
proximal colon and rectal location of tumours.  
[56] 
Adenoma Positive Current v. never smoking  
RR 2.14 (95% CI 1.86-2.46) 




Positive High v. low smoking 
exposure  
RR 2.47 (95% CI 2.12-2.87) 
Association was stronger for sessile serrated lesions 
(RR 3.40; 95% CI 1.90-6.07) than hyperplastic 
polyps (RR 2.34; 95% CI 2.00-2.73) 
[2] 
 
RR: Relative Risk. CI: Confidence Intervals. *References pertain to the risk estimates shown in the most recently published meta-analyses.           





















Figure 2.  
 
	(A)	
	(B)	
 
